Medtronic ( (MDT) ) has released its Q3 earnings. Here is a breakdown of the information Medtronic presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medtronic plc is a global leader in healthcare technology, specializing in medical devices and therapies across various medical sectors, including cardiac care and diabetes management.
In its third quarter fiscal 2025 earnings report, Medtronic showcased solid financial performance with a reported revenue of $8.3 billion, marking a 2.5% increase compared to the same period last year. The company’s growth was bolstered by advancements and strong market positions in areas such as Pulsed Field Ablation, Diabetes, and Neuromodulation.
Key financial highlights from the report include a GAAP diluted EPS increase of 2% to $1.01 and a non-GAAP diluted EPS increase of 7% to $1.39. Medtronic’s Cardiovascular Portfolio saw a revenue rise of 3.7%, driven significantly by the adoption of pulsed field ablation systems. The Neuroscience Portfolio also reported a 4.4% increase in revenue, particularly in Neuromodulation with a low-double digit growth. Despite a slight decline in its Medical Surgical Portfolio, the Diabetes segment recorded an impressive 8.4% revenue rise, underscoring the success of the MiniMed 780G system.
As Medtronic looks forward, the company maintains its revenue and EPS guidance for fiscal 2025, anticipating organic revenue growth between 4.75% and 5%. This outlook reflects confidence in continued innovation and expansion in key markets, driving both top and bottom-line growth.
Overall, Medtronic’s latest earnings report highlights its strategic advances and robust financial health, positioning it well for future growth in the competitive medtech industry.
